Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BRIDGEWATER, N.J., Nov. 7, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the granting of inducement awards to 27 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.
爱文思控股于2024年11月7日发布新闻稿称，该全球生物制药公司致力于为面临严重疾病的患者提供首创和最佳疗法，今天宣布向27名新员工授予诱导奖励。根据纳斯达克规则5635(c)(4)，这些奖励经过了爱文思控股的薪酬委员会批准，并作为每位新员工加入公司的主要诱因。
In connection with the commencement of their employment, the employees received options on November 1, 2024 to purchase an aggregate 66,740 shares of Insmed common stock at an exercise price of $68.32 per share, the closing trading price on the Nasdaq Global Select Market on the date of grant.
为配合他们的就职，员工们于2024年11月1日获得了期权，以购买爱文思控股普通股66,740股，行使价格为每股68.32美元，该价格是授予当日纳斯达克全球精选市场收盘交易价格。
The options have a 10-year term and a four-year vesting schedule, with 25% of the shares subject to the option vesting on the first anniversary of the relevant grant date and 12.5% of the shares subject to the option vesting every six months thereafter through the fourth anniversary of the relevant grant date, subject to the relevant employee's continued service with Insmed on the applicable vesting date.
该期权为期10年，有四年的解锁计划，其中约25%的股票在相关授予日期的第一周年解锁，并且每隔六个月其余的12.5%的股票将解锁，直到相关授予日期的第四年周年，取决于相关员工在适用的解锁日期之前是否继续在Insmed工作。
About Insmed
关于Insmed
Insmed Incorporated is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. The Company is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines as well as cutting-edge drug discovery focused on serving patient communities where the need is greatest. Insmed's most advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company's early-stage research programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue.
insmed公司是一家以人为本的全球生物制药公司，致力于提供一流和最佳疗法，改变患有严重疾病的患者的生活。该公司正在推进一系列已获批和中后期研究的药物以及聚焦于为需求最大的患者群体提供服务的尖端药物发现。insmed最先进的项目涉及肺部和炎症疾病，包括在美国、欧洲和日本获批用于治疗慢性、令人衰弱的肺部疾病的一种治疗方法。该公司的早期研究项目涵盖各种技术和模式，包括基因疗法、AI驱动的蛋白工程、蛋白质制造、RNA端连接和合成拯救。
Headquartered in Bridgewater, New Jersey, Insmed has offices and research locations throughout the United States, Europe, and Japan. Insmed is proud to be recognized as one of the best employers in the biopharmaceutical industry, including spending four consecutive years as the No. 1 Science Top Employer. Visit to learn more.
总部位于新泽西州布里奇沃特，insmed在美国、欧洲和日本各地设有办公室和研究场所。insmed自豪地成为生物制药行业最佳雇主之一，包括连续四年获得科学顶级雇主第一的荣誉。访问，以了解更多。
Contact:
联系方式：
Investors:
投资者:
Bryan Dunn
Executive Director, Investor Relations
(646) 812-4030
[email protected]
Bryan Dunn
执行董事，投资者关系
(646) 812-4030
[email protected]
Michael V. Morabito, Ph.D.
Director, Investor Relations
(917) 936-8430
[email protected]
Michael V. Morabito博士
投资者关系董事
(917) 936-8430
[email protected]
Gianna De Palma
Manager, Investor Relations
(873) 886-2236
[email protected]
Gianna De Palma
投资者关系经理
(873) 886-2236
[email protected]
Media:
媒体:
Mandy Fahey
Vice President, Corporate Communications
(732) 718-3621
[email protected]
Mandy Fahey
企业通信副总裁
(732) 718-3621
[email protected]
SOURCE Insmed Incorporated
Insmed Incorporated
